AbbVie (ABBV) on Wednesday said it expects a significant impact on fourth-quarter earnings due to charges related to acquired in-process research and development (IPR&D) and milestone expenses, highlighting continued financial fallout from recent deal activity.
The company reported a $1.3 billion pre-tax charge, which is set to weigh on both GAAP and adjusted earnings per share, according to a filing.
AbbVie’s fourth quarter 2025 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2025 acquired IPR&D and milestone expenses, is $2.61 – $2.65. Analysts expect EPS of $3.35/share on revenue of $16.40B.
AbbVie’s (ABBV) full-year 2025 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2025 acquired IPR&D and milestone expenses, is $9.90 – $9.94.
The disclosure follows an earlier announcement of a larger $2.7 billion charge tied to IPR&D and milestones, which affected results in Q3 2025.
